Recent advances in hematopoietic stem cell transplantation

Hematopoietic cell transplantation (HCT), once used as a last-resort therapy, is now considered a lifesaving procedure for thousands of patients with life-threatening diseases worldwide and is frequently used early in the course of treatment for diseases destined to be uncontrollable by non-HCT therapies. Incremental advances leading to reduction of post-transplant morbidity and mortality by better control of graft versus host disease (GVHD), infections, and regimen-related toxicities, coupled with greater donor options, not only significantly increased the utilization and success of this procedure but also allowed many of these patients to enjoy healthy and productive lives after HCT. Emerging concepts in the field are now focused on the expansion of available donor options, further reduction of transplant-related toxicity, and decrease in post-transplant relapse.

[1]  N. Kröger,et al.  An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. , 2017, JCI insight.

[2]  A. Logan,et al.  Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids , 2016 .

[3]  G. Salles,et al.  Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group , 2016 .

[4]  E. Estey,et al.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Catherine J. Wu,et al.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.

[6]  J. McGuirk,et al.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma , 2016, Bone Marrow Transplantation.

[7]  J. Baddley,et al.  Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.

[8]  L. Luznik,et al.  Modern approaches to HLA-haploidentical blood or marrow transplantation. , 2016, Nature Reviews Clinical Oncology.

[9]  E. Leifer,et al.  Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 , 2015 .

[10]  R. Vij,et al.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.

[11]  Shannon R. McCurdy,et al.  Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Lengerke,et al.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.

[13]  J. Ritz,et al.  Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. , 2015, Blood.

[14]  M. Martelli,et al.  Haploidentical hematopoietic stem cell transplantation: state of art , 2015, Bone Marrow Transplantation.

[15]  A. Nademanee,et al.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[16]  A. Lane,et al.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[18]  M. Norkin,et al.  Diagnostic strategies for invasive fungal infections in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  K. Ballen,et al.  Umbilical cord blood transplantation: the first 25 years and beyond. , 2013, Blood.

[20]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[21]  M. Kersten,et al.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[23]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[24]  M. Horowitz,et al.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation. , 2012, Blood.

[25]  Krishna Komanduri,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[26]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[27]  Richard J. Jones,et al.  High-dose cyclophosphamide for graft-versus-host disease prevention , 2010, Current opinion in hematology.

[28]  M. Boeckh,et al.  How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.

[29]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[30]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[31]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[32]  E. Thomas,et al.  Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. , 1957, The New England journal of medicine.

[33]  F. van Rhee,et al.  Transplantation for Multiple Myeloma. , 2016, Cancer treatment and research.

[34]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.